Longitudinal validation of ENLIGHT, an AI predictor of immunotherapy response and resistance, in pan-cancer cohorts.
An AI tool that predicts which patients will respond to immunotherapy gains stronger validation across multiple cancer types, potentially helping doctors choose treatments more accurately.
This study provides longitudinal validation of ENLIGHT, an AI tool designed to predict immunotherapy response and resistance, in diverse pan-cancer patient populations. The validation strengthens the clinical translation pathway for AI-guided patient selection for immune checkpoint inhibitor therapy.
What the study was
- Study design
- Validation study — longitudinal multi-cohort validation of AI biomarker predictor
- Population
- Adults with multiple cancer types receiving immune checkpoint inhibitor therapy
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- NPJ Precision Oncology
Why it surfaced
ENLIGHT validation is an important step toward clinical deployment of AI immunotherapy response predictors. Pan-cancer scope strengthens generalizability. Score 7/10: moderate novelty (tool exists, validation is incremental, 2), meaningful clinical relevance for immunotherapy selection (2), validation cohort design (2), broad cancer population (1).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.